Skip to main content
. 2020 May 18;12(5):459. doi: 10.3390/pharmaceutics12050459

Figure 5.

Figure 5

Effect of pirfenidone, galunisertib, and imatinib on interstitial accumulation of alpha-smooth muscle actin (α-SMA) in PCKS. (a) Representative photomicrographs of immunohistochemistry for α-SMA in murine and human PCKS before (0 h), after culture (48 h), and after treatment with pirfenidone 2.5 mM, galunisertib 10 µM, or imatinib 10 µM. Scale bars are 25 µm (murine PCKS) or 50 µm (human PCKS). Stars indicate α-SMA-positive blood vessels that were excluded from quantitative analysis. Black arrow heads point α-SMA-positive interstitial and mesangial cells in mPCKS, and show examples of α-SMA expression sites in 0 h control slices. (b) Computerized quantitative analysis of α-SMA protein expression in cortico-interstitium in PCKS, relative to 48 h control slices. Non-parametric Mann–Whitney test was used to compare α-SMA levels at 0 and 48 h (control slices), # p < 0.05. Kruskal–Wallis test followed by Dunn’s multiple comparisons test was used to compare treated PCKS with 48 h control slices, * p < 0.05. Data are expressed as mean ± SEM, n = 3–4 (murine PCKS) or n = 3–5 (human PCKS).